SK Biopharmaceuticals, a biotechnology firm focused on central nervous system and oncology treatments, has announced the formation of a new joint venture, Mentis Care, Inc., in collaboration with Eurofarma, a prominent pharmaceutical company based in Brazil. This initiative aims to commercialize an artificial intelligence (AI)-based platform designed for epilepsy management.
The announcement was made on October 21, 2025, following a launch ceremony held in Toronto, Canada, on October 20, 2025. This joint venture signifies SK Biopharmaceuticals” commitment to expanding its digital healthcare capabilities, stepping beyond its established drug development expertise.
Since 2018, SK Biopharmaceuticals has cultivated specialized knowledge in AI-enhanced electroencephalography (EEG) and wearable technologies, which facilitate seizure detection and real-time monitoring. The newly established Mentis Care will utilize these advancements to create a comprehensive digital platform that integrates real-time seizure detection and predictive algorithms with clinical decision-making tools, ultimately offering personalized care for epilepsy patients.
Located within the MaRS Discovery District in Toronto, a prominent innovation hub in North America, Mentis Care plans to expand its local workforce, enhance partnerships within academic and industry circles, and pursue clinical validation of its AI systems.
Eurofarma will spearhead business strategy and AI data integration for the venture. The collaboration builds on an existing partnership that began in 2022, focusing on the development and commercialization of the anti-seizure medication cenobamate, also known as XCOPRI® in the U.S., across Latin America.
Leading the new venture is Hassan Kotob, previously the Chief Executive Officer of Brain Scientific. Kotob brings extensive experience in healthcare and technology sectors, and he aims to advance Mentis Care“s groundbreaking AI-driven platform for predictive brain health, transforming the management and forecasting of seizures and other neurological incidents.
“Mentis Care is an AI-driven digital health company with the mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring,” stated Kotob. “By combining the innovation capabilities of our partners, SK Biopharmaceuticals and Eurofarma, we aim to establish a new standard in digital epilepsy management for patients worldwide.”
Rodrigo Pereira, Eurofarma“s Global Executive Director of Entrepreneurship and Digital, commented, “The joint venture represents the future we envision for healthcare, merging digital technologies with pharmaceuticals to significantly improve patients” lives. We have cultivated strong relationships with psychiatrists and neurologists while investing in digital innovation for our R&D activities.”
Donghoon Lee, CEO of SK Biopharmaceuticals, added, “We are expanding beyond traditional pharmaceuticals into digital healthcare to unlock new opportunities in patient care. Through Mentis Care, we will strive for patient-centered innovation by integrating AI and clinical data to enhance epilepsy treatment.”
Mentis Care aims to redefine neurological care with its pioneering AI platform, designed to detect and predict seizures in real time, thereby providing increased safety and confidence for patients and their families while setting a new standard in global brain health.
This joint venture reflects a significant shift toward integrating digital innovations in the management of epilepsy, demonstrating both companies” commitment to enhancing healthcare solutions for patients worldwide.
